ABSTRACT
To date the severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2), known as COVID-19, is for clinicians the most difficult global therapeutic problem. In this landscape, the management of patients with chronic kidney disease, acute kidney injury or patients undergoing immunosuppressant therapies for kidney transplant or glomerular diseases, represent a clinical challenge for nephrologists, especially in patients with severe acute lung involvement. Therefore in this setting, due to the lack of anti-COVID treatment schedules, tailored management is mandatory to reduce the side effects, as consequence of impaired renal function and drugs interactions. We report the main treatment actually used against SARS-CoV-2, underlining its possible use in the nephropatic patients and the central role of nephrologists to improve the clinical outcome.
Subject(s)
Coronavirus Infections/complications , Pneumonia, Viral/complications , Renal Insufficiency, Chronic/drug therapy , Adenosine Monophosphate/analogs & derivatives , Adenosine Monophosphate/therapeutic use , Adrenal Cortex Hormones/therapeutic use , Alanine/analogs & derivatives , Alanine/therapeutic use , Amides/therapeutic use , Antibodies, Monoclonal/therapeutic use , COVID-19 , Cobicistat/therapeutic use , Coronavirus Infections/drug therapy , Darunavir/therapeutic use , Drug Combinations , Humans , Kidney/drug effects , Kidney/injuries , Kidney/physiopathology , Lopinavir/therapeutic use , Pandemics , Pneumonia, Viral/drug therapy , Pyrazines/therapeutic use , Renal Insufficiency, Chronic/complications , Renal Replacement Therapy/methods , Ritonavir/therapeutic useABSTRACT
No abstract available.